The Development of a Bimodal Walking-Running Prosthetic Foot

项目摘要/摘要 在这项为期两年的第二阶段工作中，解放技术公司(LTI)及其合作者 在Fillauer公司和Hanger诊所，将改进、扩展和测试一种双峰步行跑步脚，这种脚将 然后准备成为一个可行的商业产品，可以在现有的L代码下进行报销- 报销结构。该项目的目标是创建一个单一的脚，这是优化在每种模式和 在行走模式下相当于行走的脚，在跑步模式下相当于跑步的脚。这只新奇的脚 将为目前由于缺乏运动能力而无法使用双脚的截肢者提供 保险范围、参加跑步和其他基于跑步的活动的机会(例如篮球、 等)以增加身体健康。在这样做的时候，凯撒的脚也会考虑到增加的社会 参与以及与这些活动相关的身心健康益处。 为了实现这一目标，我们将在取得以下成果的基础上，对双峰足技术进行改进和细化 以下目标：(1)迭代和优化双峰足的设计，以实现全功能的原型 准备测试，(2)进行验证测试，以确认样机符合设计标准，(3)验证 在试点带回家试验中的原型，并评估其对下肢截肢者身体活动的影响，以及 (4)开始为FDA提交的凯撒脚做准备。 结果将是在实验室和现实世界中验证和验证双峰足部装置的数据。 该产品将是一种非常先进的、商业上可行的、经过验证和验证的双峰假肢。这 创新的设计使我们能够解决两个已确定的主要障碍，阻止法援局参与 这些活动：1)假体设计不充分(通过提供优化的设计、对齐和 行走和跑步模式下的生物力学)和2)缺乏高活动度假肢的可达性 (足部费用将由保险支付)。

PROJECT SUMMARY / ABSTRACT Over the course of this two-year Phase II effort, Liberating Technologies, Inc. (LTI), along with its collaborators at Fillauer Companies and Hanger Clinic, will refine, expand, and test a bimodal walking-running foot that would then be poised to become a viable commercial product that can be reimbursed under the existing L-code reimbursement structure. The goal of this project is to create a single foot that is optimized in each mode and comparable to a walking foot when in a walking mode and a running foot when in running mode. This novel foot would provide lower limb amputees who don’t currently have the access to running feet due to the lack of insurance coverage, the opportunity to participate in running and other running-based activities (e.g. basketball, etc.) to increase physical fitness. In doing so, the Caesar foot would also allow for the increased social participation and the physical and mental health benefits that are associated with these activities. In order to achieve this goal, we will progress and refine the bimodal foot technology with the achievement of the following objectives: (1) iterate and optimize the design of the bimodal foot to achieve a fully functional prototype ready for testing, (2) perform verification testing to confirm the prototype meets the design criteria, (3) validate the prototype in a pilot take-home trial and assess its impact on the physical activity of lower limb amputees, and (4) start preparing for an FDA submission for the Caesar foot. The outcomes will be data that verify and validate the bimodal foot device in the laboratory and in the real world. The product will be a highly advanced, commercially viable, verified, and validated bimodal prosthetic foot. This innovative design allows us to address both of the identified primary barriers preventing LLAs from taking part in these activities: 1) inadequately designed prostheses (by providing a foot with optimized design, alignment, and biomechanics in both walking and running modes) and 2) the lack of accessibility for higher activity prostheses (the cost of the foot would be covered by insurance).